Unresectable Pancreatic Cancer Clinical Trial
Official title:
Open Label Randomized, Multicentre, Controlled Trial of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Patients With Unresectable Pancreatic Cancer. The PERTseverance Trial.
- This will a be an open label, multicentre, randomized, controlled study in patients with unresectable pancreatic cancer, locally advanced or metastatic, with significant weight loss, and the tumour located in the head of the pancreas associated with dilated main pancreatic duct. Pancreatic Exocrine Replacement Therapy (PERT) in these patients will be given on top of other required therapies (best standard of care, BSC), including oncologic therapies, diabetes mellitus therapies and acid suppressants and nutritional support as appropriate. The duration of the study will be up to six months. Consecutive patients meeting inclusion criteria and none of the exclusion criteria will be evaluated for the study. Those patients signing the informed consent for study participation will be randomized to one of the following two arms: - The experimental arm will receive the best standard of care (BSC) and PERT (capsules containing pancreatin 35,000 Ph.U.) at a fixed dose of 3 capsules with main meals (breakfast, lunch and dinner) and 2 capsules with snacks over 6 months. - The control arm will receive the BSC over 3 months, followed by a further 3-month open uncontrolled phase of BSC + PERT at the dose mentioned above. All patients will receive in addition a proton pump inhibitor (PPI) bid (any PPI at standard dose is acceptable -omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg, esomeprazole 40 mg) while on PERT, 20-30 minutes before breakfast and dinner. To make the two arms comparable, patients will be stratified in two groups (locally advanced and metastatic pancreatic cancer) for randomization using computer generated random numbers.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT02945267 -
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
|
Phase 4 | |
| Completed |
NCT01304160 -
Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05251038 -
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03602885 -
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
|
N/A | |
| Completed |
NCT03239184 -
Bioinformation Therapy for Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04002479 -
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
| Completed |
NCT03250273 -
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT02035072 -
Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.
|
Phase 2 | |
| Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04789486 -
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Recruiting |
NCT04093141 -
Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT06278454 -
Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)
|
Phase 1 | |
| Terminated |
NCT02166190 -
RFA RCT for Pancreatic or Bile Duct Cancer
|
N/A | |
| Completed |
NCT02282722 -
Improving Informed Consent for Palliative Chemotherapy
|
N/A | |
| Recruiting |
NCT05601323 -
A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
|
N/A | |
| Not yet recruiting |
NCT06026943 -
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer
|
N/A |